No Authorized Claim Exists for Eyes, Ears or Nerves

what are the twelve authorized health claims, in full?

FDA authorizes exactly twelve health claims under 21 CFR part 101 subpart E — the strongest lawful diet-disease link the agency grants, built on what regulators call significant scientific agreement (SSA), FDA's highest evidence bar for a food-disease relationship. We counted every entry in the subpart E index against the current GovInfo CFR text, and the table below is the complete set, section by section.

Five of the twelve name coronary heart disease outright — saturated fat and cholesterol, two separate fiber claims, soy protein, and plant sterol and stanol esters — and a sixth covers hypertension. Three cover cancer. One each covers bone, birth defects and dental decay. The cholesterol niche draws directly on that cardiovascular cluster, citing several of the six CHD- and hypertension-related claims at once; hearing, vision and nerve copy has no cluster like it to draw on.

Compare that to how FDA handled digestion. Rather than routing bloating through a formal SSA petition, the 2000 rulemaking simply blessed five phrases outright in its structure/function preamble — the page listing "alleviates bloating" as a cleared phrase shows the cheaper route FDA sometimes takes instead of the twelve-item list. No equivalent blessing exists for a symptom word tied to hearing, vision or nerve function.

why does none of them reach a sensory or nerve condition?

None of the twelve reaches ear, eye or nerve because the list traces to specific petitions that cleared FDA's significant-scientific-agreement bar decades ago, and nobody built that record for a sensory organ. Calcium and osteoporosis traces to bone-density trials. Soy protein and coronary heart disease traces to cholesterol trials. Folate and neural tube defects traces to a birth-defect prevention campaign that predates most of the direct-response supplement industry entirely. Hearing, tinnitus, vision and nerve conditions never had an equivalent petitioner push a diet-disease relationship through that same review, so the shelf simply has nothing on it for these four categories.

The gap is structural, not an oversight FDA might still correct.

Kidney function has the identical hole in the list — not one authorized claim, not one qualified claim, only a narrow urinary-tract cranberry claim survives nearby. The pattern across all five gaps is the same: FDA's twelve claims cluster around conditions with decades of population-level nutrition research behind them, and the ear, eye, nerve and kidney simply never generated that research trail through a food-industry petitioner.

what is the difference between an authorized claim and structure/function here?

An authorized health claim, cleared through FDA's significant-scientific-agreement standard, lets you say a product "reduces the risk of" a named disease. A structure/function claim, the DSHEA-era statement about normal body function, cannot mention risk reduction or any disease at all — it can only describe how a nutrient maintains function, and it must carry the mandatory disclaimer that FDA has not evaluated the statement. For hearing, tinnitus, vision and nerve health, only the second route exists, because the first was never built for these conditions and the third route — the qualified health claim — was tried once and rejected, which the next section covers.

FDA reads context, not vocabulary, when it decides which side of that line a claim lands on. Its own rule states plainly: "In determining whether a statement is a disease claim under these criteria, FDA will consider the context in which the claim is presented." Swap the words but keep a symptom cluster or a diagnosis-shaped image next to them, and a lawful structure/function sentence about nerve function reads as a disease claim anyway.

can a qualified health claim be borrowed the way blood sugar offers borrow chromium?

No. The borrowing move that works in blood sugar supplements has no equivalent here. FDA's qualified health claim (QHC) programme lets an advertiser use weak, preliminary evidence to make a disease-adjacent claim, as long as FDA's own skepticism rides along in the same sentence. In blood sugar copy that route runs through chromium picolinate; in cognitive-decline copy it runs through phosphatidylserine, where the mandated wording forces the brand to publish FDA's own verdict: "FDA concludes that there is little scientific evidence supporting this claim."

We checked FDA's ledger of qualified health claims — nine subject categories in total — for the four sensory and nerve conditions and found one filing, not nine. FDA denied it. The petition was titled "Xangold® Lutein Esters, Lutein, or Zeaxanthin and Reduced Risk of Age-related Macular Degeneration or Cataract Formation," filed for an eye disease, and FDA's Letters of Denial closed it on December 19, 2005. Two decades later, no replacement filing has succeeded — for eyes, ears or nerves.

what does 'reduces the risk of' cost an advertiser in these four niches?

It costs the product its supplement status entirely. "Reduces the risk of" is legally available only through an authorized or qualified health claim, and both routes are closed for ear, eye and nerve conditions, so the phrase has nowhere lawful to land. Say it about tinnitus, macular degeneration or neuropathy and the product is now marketed as a drug under 21 CFR 101.93(g)(2)(i), evaluated the same way FDA evaluated the disease claims cited in its AlzClipp and BergaMet warning letters.

There is no hedge that fixes this.

Softening the verb doesn't reopen the route, because the exposure attaches to the disease reference, not to the strength of the promise. "May help reduce the risk of hearing loss," "could lower the risk of nerve damage," and "shown to reduce the risk of macular degeneration" all name a disease outcome that no claim category currently authorizes for that organ. FDA has repeatedly cited hedged phrasing as drug evidence in cases spanning cholesterol, cognition and thyroid copy, and a sensory-condition version would almost certainly read no differently to an agency reviewer.

how does the ftc substantiation bar apply on top of this?

It applies whether or not FDA has authorized anything, because the two agencies run separate tests. Even a lawful structure/function claim — "supports normal auditory function," say — still needs FTC-grade evidence behind it, and the FTC's Health Products Compliance Guidance sets that bar at clinical trial data: "substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing."

So an ear-health capsule can clear FDA's structure/function line and still be an FTC violation if the only backing is an animal study or an in vitro assay. The doctrine that catches implied disease claims from context alone works the same way on the substantiation side: a claim you never wrote in words but conveyed through imagery or symptom framing still needs the same clinical-trial evidence a bald statement would need, and there is no smaller evidence bar for the softer version of the claim.

what is the only lawful register left for an ear, eye or nerve offer?

The only lawful register is a bare, symptom-free statement that the product supports the organ's normal function — nothing else survives across all four conditions. "Supports normal auditory function," "supports eye health," and "supports nerve function" sit inside 21 CFR 101.93(f), FDA's carve-out for claims about maintaining, not fixing, a bodily system. The same trap that catches thyroid copy applies here too: a symptom list is a disease claim under FDA's own criteria even when the disease word never appears, so the moment your copy names ringing, blurred vision, tingling or numbness, the safe phrasing above it stops mattering.

Vision is a partial exception, and it's worth stating precisely. FDA's 2000 rulemaking names presbyopia — the normal, age-related loss of near focus — as an example condition open to structure/function claims, the only sensory condition FDA ever named that way. It never extended the same courtesy to age-related hearing loss, called presbycusis in the clinical literature, even though the two conditions are close analogues in how they present; the word "hearing" appears only twice in the entire rulemaking, and neither mention addresses aging at all.

We could not find a published FDA example letter or guidance document applying that presbyopia-style carve-out to hearing by name. A future structure/function example letter that named presbycusis explicitly is what would settle whether the 2000 omission was deliberate policy or just an accident of which petitioner showed up that year — until one exists, treat age-related hearing copy as unprotected by any equivalent to the presbyopia line.

Nerve pain gets no aging carve-out at all, because neuropathy claims are evaluated under 21 CFR 101.93(g)(2)(i)-(ii) — effect on a specific disease, or on its characteristic signs and symptoms — not under the natural-state provision that gives vision and hair loss their opening. There's no "common condition of aging" argument available for burning, tingling or numbness the way there arguably is for a stiff near-focus or a thinning hairline, so nerve copy has the narrowest lawful register of the four: function-maintenance language only, with no symptom word anywhere on the page.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Where the Sleep Apnea Disclaimer Has to Sit, Insomnia in a Bundle Is Still a Drug Claim, Ingredient Studies Do Not Substantiate Your Formula, Occasional Constipation Is Allowed, With a Condition, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.